KRAS, one of cancer’s toughest targets, sees a surge of new therapies trying to limit side effects: #AACR23
ORLANDO – Two years after Amgen won approval for a drug going after one of cancer’s most frustrating genetic targets, researchers believe they’re finally beginning …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.